北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2024 年年度股东大会的 法律意见书 二零二五年五月 | 北京总部 | 电话: (86-10) 8519-1300 | 上海分所 | 电话: (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: (86-10) 8519-1350 | | 传真: (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: (86-571) 2689-8188 | 成都分所 | 电话: (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: (86-571) 2689-8199 ...

本次回购注销部分限制性股票实施完毕后，公司注册资本将相应减少。根据 《中华人民共和国公司法》和《公司章程》的相关规定，公司特此通知债权人， 债权人自本公告披露之日起 45 日内，有权要求公司清偿债务或者提供相应担保。 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和 国公司法》等相关法律法规的规定，向公司提出书面要求，并附随有关证明文件。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于注销回购股份减少注册资本暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 5 月 9 日，广州万孚生物技术股份有限公司（以下简称"公司"） 召开 2024 年度股东大会，审议通过了《关于调整 2024 年限制性股票激励计划 的回购价格及回购注销部分限制性股票的议案》，鉴于公司 2024 年限制性股票 激励计划部分激励对象已离职不满足激励对象资格，本激励计划首 ...

Group 1 - Company closed at 20.93 yuan on May 6, with a 1.65% increase and a rolling PE ratio of 18.92 times, resulting in a total market value of 10.076 billion yuan [1] - The average PE ratio for the medical device industry is 48.90 times, with a median of 36.41 times, placing the company at the 44th position in the industry ranking [1] - The company experienced a net outflow of 3.0741 million yuan in main funds on May 6, with a total outflow of 3.2506 million yuan over the past five days [1] Group 2 - For Q1 2025, the company reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company is recognized as a key high-tech enterprise under the National Torch Program and has received various certifications, including being one of the first domestic in vitro diagnostic reagent companies to pass FDA on-site audits [1] - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and prenatal testing, and drug abuse testing [1]

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-025 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于公司向银行申请综合授信并为经销商融资提供担保的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"）因开 展日常经营业务所需，提出了《关于公司向银行申请综合授信并为经销商融资 提供担保的议案》，该议案已经公司第五届董事会第九次会议和第五届监事会第 七次会议审议通过。公司于2025年4月9日在巨潮资讯网（www.cninfo.com.cn） 披露了《关于公司向银行申请综合授信并为经销商融资提供担保的公告》 （2025-012），现对上述公告中"参股公司其他股东担保情况"内容信息进行补 充,补充后具体内容如下（补充部分见楷体加粗字体）： 一、本次申请综合授信并为经销商融资提供担保的情况： 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"）因开 展日常经营业务所需，向中国工商银行股份有限公司 ...

万孚生物（300482）公告，2025年第一季度营收为8亿元，同比下降7.06%；净利润为1.89亿元，同比下 降13.37%。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥800,275,782.51, a decrease of 7.06% compared to ¥861,092,255.54 in the same period last year[5] - Net profit attributable to shareholders was ¥189,135,410.14, down 13.37% from ¥218,334,248.48 year-on-year[5] - Basic earnings per share decreased by 20.41% to ¥0.39 from ¥0.49 in the same period last year[5] - Total operating revenue for the current period was ¥800,275,782.51, a decrease of 7.06% from ¥861,092,255.54 in the previous period[18] - Net profit for the current period was ¥190,072,222.04, a decline of 13.75% compared to ¥220,443,620.50 from the previous period[19] - Earnings per share (EPS) for the current period was ¥0.39, down from ¥0.49 in the previous period[20] Cash Flow - The net cash flow from operating activities was -¥148,787,719.58, a significant decline of 231.41% compared to ¥113,224,704.67 in the previous year[5] - Cash inflow from operating activities totaled ¥557,099,837.33, a decrease of 25.06% from ¥743,368,930.59 in the previous period[22] - The net cash flow from operating activities was -$148.79 million, a decrease from $113.22 million in the previous period[23] - The cash outflow for operating activities totaled $705.89 million, compared to $630.14 million previously[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,182,545,912.53, reflecting a slight increase of 0.39% from ¥7,154,652,043.13 at the end of the previous year[5] - Current assets totaled CNY 3,824,674,042.04, up from CNY 3,785,861,965.80 at the start of the period[14] - Total current liabilities decreased to CNY 661,546,113.92 from CNY 821,464,141.00, indicating a reduction of approximately 19.5%[15] - The company’s total liabilities decreased to CNY 1,239,504,273.17 from CNY 1,392,436,610.63, indicating a reduction of approximately 11%[15] - Total liabilities amounted to ¥1,342,322,632.33, a decrease from ¥1,504,364,037.54[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,296[11] - The company’s equity position remains strong, with significant holdings by major shareholders, including Li Wenmei at 20.32% and Wang Jihua at 10.30%[13] - Total equity attributable to shareholders of the parent company increased to ¥5,743,386,505.55 from ¥5,554,388,042.84[16] Changes in Financial Metrics - The weighted average return on equity was 3.35%, down from 4.50% in the previous year[5] - The company reported a significant increase in accounts receivable by 89.06%, reaching ¥27,575,749.01 due to increased sales revenue settled by notes[9] - The company experienced a 62.99% decrease in cash and cash equivalents, totaling ¥306,674,463.35, primarily due to investments in financial products[9] - The company recorded a 1217.59% increase in fair value gains, amounting to ¥11,431,121.13, attributed to the fair value changes of trading financial assets[9] Inventory and Other Assets - Inventory decreased to CNY 319,592,386.44 from CNY 359,555,274.55, representing a decline of about 11.1%[14] - The company’s non-current assets totaled CNY 3,357,871,870.49, down from CNY 3,368,790,077.33[15] Accounting and Audit - The company did not undergo an audit for the first quarter report[24] - The new accounting standards will be implemented starting in 2025, affecting the financial statements[24]

海外业务收入高速增长，商业化进展成绩亮眼 2024 年，公司海外实现收入11.03 亿元，同比增长43.23%。（1）慢病管理检测：海外收入实现同比快 速增长。公司持续深化"一带一路"沿线发展中国家的市场深耕，在中小型医疗机构领域形成差异化竞争 优势，扩大终端市场份额。（2）传染病检测：在发展中国家，公司聚焦传染病检测公卫市场，深化与 政府及国际卫生组织的合作，扩大在血源性传染病等领域的市场份额。在美国，呼吸道检测业务取得了 突破性进展，公司的新型冠状病毒、甲型流感病毒及乙型流感病毒三联检测试剂盒（POC 版）/三联家 庭检测试剂盒（OTC 版）产品获得美国FDA EUA 授权，并于2025年1 月获得美国FDA 510（k）许可。 此外，公司的新冠抗原检测产品（OTC版）于2024 年9 月获得美国FDA 510（k）许可。 事件：近日，公司发布2024 年年报：2024 年实现营业收入30.65 亿元，同比上涨10.85%，主要系国际 业务增长带动；归母净利润5.62 亿元，同比上涨15.18%；扣非归母净利润4.97 亿元，同比上涨 19.90%。 其中，2024 年第四季度营业收入8.83 亿元，同比 ...

Core Viewpoint - The Shenzhen Stock Exchange held its first collective performance briefing for listed companies in 2024, focusing on the theme "New Growth for Enterprises: Private Enterprises Competing in the Middle Stream," showcasing the latest developments of private enterprises and addressing investor concerns regarding technological innovation, tariff challenges, internationalization, and development strategies [1]. Group 1: Technological Innovation - Innovation is identified as the core driving force for the development of the private economy, with Shenzhen's private listed companies making significant investments in R&D, technology innovation, and patent accumulation [3]. - Jianfan Bio focuses on the R&D, production, and sales of biomedical materials and high-tech medical devices, particularly excelling in blood purification technology, and plans to enhance production management and diversify its product line [3]. - ZhiJian Electronics, a leader in consumer lithium-ion batteries, is committed to a forward-looking R&D strategy and aims to enhance its core competitive advantages while exploring market growth opportunities [3]. - Wanfu Bio sees digital pathology as a significant transformation opportunity and is developing comprehensive digital pathology solutions to reduce doctors' workloads [4]. - Xinlitai is exploring AI applications in drug discovery and clinical research to improve innovation efficiency and plans to deepen AI's role in drug design and data mining [4]. Group 2: Tariff Challenges - Companies are closely monitoring international trade policies and are implementing measures such as increasing domestic sales and developing new overseas markets to mitigate the impact of high tariffs imposed by the U.S. [6]. - Zongshen Power reported that its domestic sales accounted for 51.99% of total revenue in 2024, slightly higher than export business, and has taken proactive measures to address tariff risks [6]. - Yunjigroup highlighted that its supply chain has a high localization rate, effectively mitigating tariff fluctuations, and is capitalizing on new overseas projects due to the ongoing high prosperity cycle in the mining industry [7]. - Jianfan Bio is expanding into new markets while increasing its overseas business share, particularly in heavy liver disease and critical illness applications [7]. - Wanfu Bio has over 20 years of experience in international markets and continues to innovate to maintain growth in its international business despite tariff challenges [7]. Group 3: Development Trends - Shenzhen's private listed companies demonstrate resilience and vitality, with a significant number of companies contributing to economic development and technological innovation [9]. - As of March 2025, there are 2,181 private listed companies in Shenzhen, accounting for 76% of the total, with a combined market value of 22.65 trillion yuan, representing 69% of the total market value [9]. - In 2023, 582 private enterprises disclosed their annual reports, achieving a total revenue of 6.25 trillion yuan, a year-on-year increase of 6.62%, and a net profit of 419.9 billion yuan, a growth of approximately 1% [9]. - Jianfan Bio is investing in high-value resin and medical device projects, aiming to enhance market share and secure product supply [10]. - Xinlitai is transitioning from generic to innovative drugs, with increasing revenue contributions from new patented products [11].

债券代码：123064 债券简称：万孚转债 证券代码：300482 证券简称：万孚生物 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他： | | 参与单位名称及 | 深圳证券交易所及线上、线下参会的投资者 | | 人员姓名 | | | 时间 | 2025 年 4 月 18 日 | | 地点 | 深圳证券交易所 8 楼上市大厅 | | 上市公司接待人 | 董事长：王继华 | | 员姓名 | 董事会秘书：胡洪 | | | 一、公司基本情况及 2024 年全年经营情况介绍 | | | 公司 1992 年成立，深耕体外诊断领域 30 余年，提供快速诊断试剂及配 | | | 套仪器的研发、生产制造、营销及服务，致力于提升优质医疗的可及性、便捷 | | | 性和可负担性。目前公司依托九大技术平台形成了心脑血管疾病、炎症、肿瘤、 | | | 传染病、毒检、优生优育等检验领域丰富的产品线，拥有广州、杭州、香港、 | | ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-021 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于万孚转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 转股价格：人民币 27.00 元/股 转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）中相关约定：在本次发行的可转换公司 债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 80%时，公司董事会有权提出转股价格向下修正方案并 提交公司股东大会表决。上述方案须经出席会议的股东所持表决权的三分之二以 上通过方可实施。 广州万孚生物技术股份有限公司（以下简称"公司"）股票自 2025 年 4 月 7 ...